Explore More About Patient-Reported Outcomes
HDx enabled by Theranova dialyzer has shown improvements in patient-reported outcomes including symptom burden, restless legs syndrome criteria, pruritus and dialysis recovery time.1-3
Importance of patient-reported measures
The substantial increase of dialysis trials reveals inconsistent study design and reporting, making it more challenging to apply outcomes that improve the health and quality of life of dialysis patients. Without consistent trial parameters derived from research, clinical experience, and patient preferences, the needs of the patient and the option of better treatment outcomes will continue to remain in the background.4
Lim JH, Park Y, Yook JM, et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients.
HDx enabled by Theranova dialyzer may improve patient-reported outcomes, particularly in the physical domains of QOL and uremic pruritus, through efficient removal of middle molecules, in stable maintenance HD patients.1
Alarcon JC, Bunch A, Ardila F, et al. Impact of medium cut-off dialyzers on patient-reported outcomes (PROs): COREXH registry.
Expanded clearance of middle molecular uremic toxins with Theranova dialyzer may improve patient-reported health-related quality-of-life (HRQoL) outcomes including symptom burden, and restless legs syndrome criteria.2
Bolton S, Gair R, Nilsson, et al. Clinical assessment of dialysis recovery time and symptom burden: impact of switching hemodialysis therapy mode.
Sustained improvements in patient-reported post-dialysis recovery time and POS-S Renal fatigue score were observed over a 12-month period after a switch from regular HD/HDF using high-flux membranes to HDx therapy using the MCO membrane. Switching to HDx therapy with the MCO membrane led to a sustained, clinically relevant decrease in patient-reported recovery time after dialysis and a decrease in fatigue levels.3
Penny JD, Jarosz P, Salerno FR, Lemoine S, McIntyre CW. Impact of expanded hemodialysis using medium cut-off dialyzer on quality of life: application of dynamic patient-reported outcome measurement tool.
Patients with lower LEVIL scores (<70/100) at baseline showed improvement in overall HRQoL after 8 weeks of therapy with similar carryover effect. General well-being, energy, and sleep quality were improved significantly as a consequence of HDx therapy. There were no detrimental effects of HDx therapy detected in patients with higher baseline HRQoL.5
Interested in learning more?
Contact Vantive to learn more about HDx therapy enabled by Theranova dialyzer.
Important Safety Information
Indications for Use: THERANOVA dialyzers are indicated for treatment of chronic and acute renal failure by Hemodialysis.
Caution: Do not use THERANOVA dialyzers for HDF (hemodiafiltration) or HF (hemofiltration) due to higher permeability of larger molecular weight proteins such as albumin.
For safe and proper use of the device, please refer to the Instructions for Use.
Vantive, HDx, MCO and Theranova are trademarks of Vantive Health LLC or its affiliates.
References
-
Lim JH, Park Y, Yook JM, et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance haemodialysis patients. Nature/Sci Rep. 2020;10:7780.
-
Alarcon JC, Bunch A, Ardila F, et al. Impact of medium cut-off dialyzers on patient-reported outcomes (PROs): COREXH Registry. Blood Purif. 2020;50(1):110–118.
-
Bolton S, Gair R, Nilsson LG, Matthews M, Stewart L, McCullagh N. Clinical assessment of dialysis recovery time and symptom burden: impact of switching haemodialysis therapy mode. Patient Relat Outcome Meas. 2021;12:315-321.
-
Standardised Outcomes in Nephrology (SONG). HD Core Outcomes. 2020. https://songinitiative.org/hd-core-outcomes/.
-
Penny JD, Jarosz P, Salerno FR, Lemoine S, McIntyre CW. Impact of expanded haemodialysis using medium cut-off dialyzer on quality of life: application of dynamic patient-reported outcome measurement tool. Kidney Med. 2021; 3(6):992-1002.e1.